INBRIJA Drug Patent Profile

Which patents cover Inbrija, and when can generic versions of Inbrija launch?

Inbrija is a drug marketed by Merz and is included in one NDA. There are six patents protecting this drug.

This drug has one hundred and twenty-nine patent family members in twenty-two countries.

The generic ingredient in INBRIJA is levodopa. There are eighteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the levodopa profile page.

DrugPatentWatch^® Generic Entry Outlook for Inbrija

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 16, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for INBRIJA

International Patents:	129
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	134
Drug Prices:	Drug price information for INBRIJA
What excipients (inactive ingredients) are in INBRIJA?	INBRIJA excipients list
DailyMed Link:	INBRIJA at DailyMed

See drug prices for INBRIJA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for INBRIJA

Constraining patent/regulatory exclusivity:

8,545,878

NDA:

209184

Dosage:

POWDER;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for INBRIJA

Drug Class

Aromatic Amino Acid

US Patents and Regulatory Information for INBRIJA

INBRIJA is protected by six US patents.

This potential generic entry date is based on patent 8,545,878.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merz	INBRIJA	levodopa	POWDER;INHALATION	209184-001	Dec 21, 2018		RX	Yes	Yes	12,458,615
Merz	INBRIJA	levodopa	POWDER;INHALATION	209184-001	Dec 21, 2018		RX	Yes	Yes	8,945,612		Y
Merz	INBRIJA	levodopa	POWDER;INHALATION	209184-001	Dec 21, 2018		RX	Yes	Yes	RE43711
Merz	INBRIJA	levodopa	POWDER;INHALATION	209184-001	Dec 21, 2018		RX	Yes	Yes	8,685,442		Y

Expired US Patents for INBRIJA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merz	INBRIJA	levodopa	POWDER;INHALATION	209184-001	Dec 21, 2018	9,155,699
Merz	INBRIJA	levodopa	POWDER;INHALATION	209184-001	Dec 21, 2018	6,514,482
Merz	INBRIJA	levodopa	POWDER;INHALATION	209184-001	Dec 21, 2018	7,146,978
Merz	INBRIJA	levodopa	POWDER;INHALATION	209184-001	Dec 21, 2018	6,858,199

EU/EMA Drug Approvals for INBRIJA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Acorda Therapeutics Ireland Limited	Inbrija	levodopa	EMEA/H/C/004786Inbrija is indicated for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor.	Authorised	no	no	no	2019-09-19

International Patents for INBRIJA

When does loss-of-exclusivity occur for INBRIJA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Denmark

European Patent Office

Hong Kong

Japan

Mexico

New Zealand

Poland

Portugal

Russian Federation

Singapore

South Africa

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering INBRIJA around the world.

Country	Patent Number	Title	Estimated Expiration
Russian Federation	2015121092	КАПСУЛЫ, СОДЕРЖАЩИЕ ВЫСОКИЕ ДОЗЫ ЛЕВОДОПЫ, ДЛЯ ПРИМЕНЕНИЯ ПУТЕМ ИНГАЛЯЦИИ (HIGH DOSE LEVODOPA CAPSULES FOR PULMONARY USE)
World Intellectual Property Organization (WIPO)	2014074797
Cyprus	1118851
Russian Federation	2015121091	ПОРОШКИ ДЛЯ ИНГАЛЯЦИИ С УЛЬТРАНИЗКОЙ ПЛОТНОСТЬЮ (ULTRA LOW DENSITY INHALATION POWDERS)

Supplementary Protection Certificates for INBRIJA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3209302	LUC00304	Luxembourg		PRODUCT NAME: COMBINAISON DE FOSLEVODOPA ET DE FOSCARBIDOPA, CHACUNE SOUS TOUTES SES FORMES PROTEGEES PAR LE BREVET DE BASE; MARKETING AUTHORISATION NUMBER AND DATE: 141371, 20220826
3209302	202340008	Slovenia		PRODUCT NAME: COMBINATION OF FOSLEVODOPA OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND FOSCARBIDOPA OR ITS PHARMACEUTICALLY ACCEPTABLE SALT; NATIONAL AUTHORISATION NUMBER: H/05/00514/002; DATE OF NATIONAL AUTHORISATION: 20221215; AUTHORITY FOR NATIONAL AUTHORISATION: SI; FIRST AUTHORISATION IN THE EUROPEAN ECONOMIC AREA: 141371; DATE OF FIRST AUTHORISATION IN THE EUROPEAN ECONOMIC AREA: 20220825; AUTHORITY OF FIRST AUTHORISATION IN THE EUROPEAN ECONOMIC AREA: AT
3209302	C202330028	Spain		PRODUCT NAME: COMBINACION DE FOSLEVODOPA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA Y FOSCARBIDOPA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISM.; NATIONAL AUTHORISATION NUMBER: 88677-SE/H/0415/003/DC; DATE OF AUTHORISATION: 20230220; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): 141371; DATE OF FIRST AUTHORISATION IN EEA: 20220825
3209302	23C1035	France		PRODUCT NAME: COMBINAISON DE FOSLEVODOPA ET DE FOSCARBIDOPA, CHACUNE DANS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; NAT. REGISTRATION NO/DATE: 34009 302 790 8 3 20230901; FIRST REGISTRATION: AT - 141371 20220826

Last updated: May 28, 2026

INBRIJA (levodopa inhalation powder) market dynamics and financial trajectory (2017–2024)

INBRIJA (levodopa inhalation powder) has remained a niche Parkinson’s disease (PD) rescue therapy with limited payer footprint and constrained prescriber share, but it has avoided major downside milestones. The trajectory since launch is defined by (1) slow specialty uptake versus oral levodopa, (2) reimbursement friction for an inhaled delivery system, (3) manufacturing and distribution reliability tied to inhalation powder supply chains, and (4) incremental growth from treatment protocol changes rather than broad label expansion. Through 2023–2024, the product’s financials track a “small base expanding modestly” pattern rather than an inflection-driven scale story.

What is INBRIJA and what market does it address?

INBRIJA is an inhaled levodopa formulation indicated as a treatment for “off” episodes in adult patients with Parkinson’s disease receiving carbidopa/levodopa. It is a rescue option intended for rapid onset after breakthrough “off” periods, targeting a segment where rapid symptom control is clinically valued and where switching costs are tied to device learning, payer policies, and clinician familiarity.

---

How has INBRIJA performed financially since launch?

Bottom line: INBRIJA revenue growth has been steady but modest. The product has not achieved broad category share typical of first-line PD therapies and instead has operated within a smaller “rescue” budget pool where formulary placement and prior authorization determine demand.

Revenue profile and trajectory by period

Period	Market dynamic	Likely demand driver	Net effect on revenue
2017–2019	Post-launch ramp in specialty clinics	Early adopters among neurologists managing motor fluctuations	Baseline revenue creation, slow uptake
2020–2021	Continued reliance on formulary access	Stable rescue use; disruptions from health system variability	Gradual growth with limited step-change
2022	Payer and channel consolidation	Maintenance of coverage where already established	Moderate expansion
2023–2024	Niche product economics	Incremental patient volume and protocol adoption	Continued modest growth; no large inflection signaled

Key point for modeling: INBRIJA’s revenue is structurally sensitive to payer coverage (step therapy and prior authorization), because it competes with established oral “off” rescue strategies and because many payers treat inhaled products as non-preferred unless clinical criteria are met.

---

What drives INBRIJA demand in Parkinson’s disease “off” episode management?

Core drivers: clinical need for fast rescue dosing, neurologist willingness to add an inhaled option, and payer willingness to cover rescue use at acceptable reimbursement rates.

Clinical protocol dynamics that affect utilization

• Patient selection: typically patients with motor fluctuations inadequately controlled by optimized oral levodopa/carbidopa regimens.
• Rescue behavior: “off” episode frequency and caregiver routines influence switching from tablets to inhaled rescue.
• Treatment adherence: device use training and correct inhalation technique affect perceived efficacy, which then affects retention and repeat prescribing.

Payer dynamics

• Formulary status: preference vs non-preference determines prior authorization volume and denial risk.
• Authorization criteria: payers often require documentation of motor fluctuations and adequate trials of oral alternatives.
• Site-of-care economics: reimbursement can differ across outpatient specialty pharmacies and medical benefit strategies (where applicable), impacting net realized revenue.

---

What market constraints limit INBRIJA scale?

Scale constraints have been the consistent limiter: it is a device-linked, niche rescue therapy rather than a broad chronic maintenance treatment.

Non-technical constraints

• Limited addressable population at launch: “off” episode rescue need exists, but many patients are treated effectively with oral strategies or different formulations.
• Switching friction: clinicians and payers prefer continuity with oral regimens; inhaled rescue requires retraining and coverage approvals.
• Inventory and supply chain sensitivity: inhalation powder manufacturing and distribution must be reliable; any disruptions can quickly suppress demand since the product is rescue-based.

Competitive substitution pressure inside “rescue” space

INBRIJA competes against:

• Oral rescue strategies (rapid-acting oral options, optimized dosing schedules).
• Device- or infusion-based rescue alternatives where available via payer preference.
• Adjustments to baseline carbidopa/levodopa regimens that reduce “off” frequency and therefore reduce rescue need.

---

How do reimbursement and formulary placement affect INBRIJA net sales?

Answer: reimbursement is the primary swing factor for net revenue in niche PD products. Coverage determines whether prescriptions convert to shipped doses, and prior authorization creates execution risk.

Typical reimbursement pathways shaping demand

• Commercial plans: most frequently control access through step edits, prior authorization, and preferred drug lists.
• Specialty pharmacy channel: net sales depend on wholesaler buy-in, specialty fulfillment speed, and chargeback dynamics.
• Denials and appeals: can suppress utilization even when prescriptions are written.

Business implication: even when clinical adoption grows, net sales can lag if coverage breadth does not expand at the same rate.

---

What is the competitive landscape for INBRIJA by therapeutic role?

Competitive role: rescue therapy for “off” episodes in PD patients on carbidopa/levodopa.

Competitive comparison framework (revenue-relevant)

Competitor class	How it substitutes for INBRIJA	Key payer lever	Effect on INBRIJA
Oral rescue additions	Patients can take additional oral doses	Oral products usually preferred	Increases resistance to switching
Other PD “off” episode rescue tools	Different onset profile, sometimes different administration setting	Coverage and formulary hierarchy	Limits capture rate
Optimization of baseline dosing	Reduces frequency of rescue episodes	Treats root cause	Can reduce rescue demand pool

---

What are the key drivers of INBRIJA’s unit economics and margin trajectory?

Answer: unit economics depend on realized price after rebates/discounts, distribution and specialty pharmacy handling costs, and the cost structure of inhalation powder manufacturing.

What moves gross-to-net

• Rebates/discounts: higher with expanded coverage and more payer negotiation cycles.
• Chargebacks: influenced by channel composition.
• Mix shift: increasing share of patients on particular payer contracts can raise or lower realized price.

Manufacturing and supply reliability

Inhalation powder products are sensitive to:

• Yield and batch consistency
• Packaging and device compatibility
• Regional distribution constraints Any constraint can cause short-term lost shipments with disproportionate effect in rescue products where patients rely on continuous access.

---

What about INBRIJA inventory, supply, and execution risk in the market?

Execution risk is revenue-relevant because INBRIJA is used for breakthrough rescue episodes, not daily adherence in most patients.

Supply-demand timing sensitivity

• Rescue products create “need on demand.” If inventory is constrained, prescribers may hesitate to place patients on the product long-term, and payers may delay coverage if fulfillment reliability is poor.
• Specialty pharmacy fill rates and lead times directly impact continuation.

---

How might patent life and exclusivity affect market pricing power and future financial trajectory?

Answer: patent and exclusivity status determine time horizons for price competition and generic/branded erosion risk. However, this prompt asks for market dynamics and financial trajectory; without reliable, specific exclusivity and Orange Book data for INBRIJA included here, a precise “when exclusivity expires” timeline cannot be produced in a way that is accurate and decision-grade.

---

What is the expected forward financial trajectory for INBRIJA (base case)?

Base case: modest growth constrained by niche use, with earnings profile tied to gross-to-net discipline and supply reliability.

Forward-looking model drivers (what changes the slope)

1. Coverage expansion: new formulary wins or reduced prior authorization barriers would raise conversion of prescriptions to paid claims.
2. Protocol adoption: higher “off episode rescue” utilization per patient.
3. Competitive response: new PD rescue entrants, or payer shifts back toward preferred oral options.
4. Supply continuity: fewer stock-outs and stable fulfillment.

Reverse indicators (what would flatten revenue)

• Widening prior authorization tightening
• Evidence of substitution back to oral rescue strategies
• Any persistent supply constraint affecting ship volume

---

Key Takeaways

• INBRIJA is a niche PD “off episode” rescue therapy with demand shaped primarily by payer coverage and specialty execution rather than broad chronic PD market penetration.
• The financial trajectory since launch is best characterized as slow ramp followed by modest, incremental growth, with no clear hallmark inflection described in the available data framing.
• Supply reliability, prior authorization dynamics, and unit economics (gross-to-net) drive net sales more than pure clinical adoption.
• The product’s forward growth rate remains sensitive to formulary breadth and execution stability; competitive substitution within rescue strategy choices limits upside.

---

FAQs

1) Why do “off episode” rescue therapies like INBRIJA grow slowly even when neurologists prescribe them?
Coverage friction and patient selection drive conversion from prescriptions to filled, reimbursed use.

2) What payer behaviors most affect INBRIJA demand?
Prior authorization, step edits toward oral alternatives, and preferred drug list placement determine realized demand.

3) How do supply disruptions impact revenue for rescue inhalation products?
Rescue use depends on availability at the moment of need; stock-outs suppress continuity, which then reduces future prescribing.

4) What competitive substitutions most threaten INBRIJA?
Oral rescue optimization and alternative PD “off” rescue strategies with preferred formulary status.

5) What indicators best predict whether INBRIJA net sales will accelerate?
Expansion of coverage breadth, improved specialty pharmacy fill rates, and sustained increases in per-patient rescue utilization.

---

References (APA)

1. (No citable sources were provided in the prompt, and no external patent/FDA/Orange Book or financial filings were supplied to support a data-accurate financial trajectory for INBRIJA.)